<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">medRxiv</journal-id><journal-id journal-id-type="publisher-id">MEDRXIV</journal-id><journal-title-group><journal-title>medRxiv</journal-title></journal-title-group><publisher><publisher-name>Cold Spring Harbor Laboratory</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39974050</article-id><article-id pub-id-type="pmc">PMC11838657</article-id>
<article-id pub-id-type="doi">10.1101/2025.01.30.25321017</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chin</surname><given-names>Daniel</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Hernandez-Beeftink</surname><given-names>Tamara</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Donoghue</surname><given-names>Lauren</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Guillen-uio</surname><given-names>Beatriz</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Leavy</surname><given-names>Olivia C</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Adegunsoye</surname><given-names>Ayodeji</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Booth</surname><given-names>Helen L</given-names></name><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><collab>CleanUP-IPF Investigators of the Pulmonary Trials Cooperative</collab><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Fahy</surname><given-names>William A</given-names></name><xref rid="A9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Fingerlin</surname><given-names>Tasha E</given-names></name><xref rid="A10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Gooptu</surname><given-names>Bibek</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Hall</surname><given-names>Ian P</given-names></name><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>Hart</surname><given-names>Simon P</given-names></name><xref rid="A12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>Mike R</given-names></name><xref rid="A13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name><surname>Hirani</surname><given-names>Nik</given-names></name><xref rid="A14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name><surname>Hubbard</surname><given-names>Richard B</given-names></name><xref rid="A15" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>Simon</given-names></name><xref rid="A16" ref-type="aff">16</xref></contrib><contrib contrib-type="author"><name><surname>Kaminski</surname><given-names>Naftali</given-names></name><xref rid="A17" ref-type="aff">17</xref></contrib><contrib contrib-type="author"><name><surname>Lorenzo-Salazar</surname><given-names>Jose Miguel</given-names></name><xref rid="A18" ref-type="aff">18</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Shwu-Fan</given-names></name><xref rid="A19" ref-type="aff">19</xref></contrib><contrib contrib-type="author"><name><surname>McAnulty</surname><given-names>Robin J</given-names></name><xref rid="A20" ref-type="aff">20</xref></contrib><contrib contrib-type="author"><name><surname>McCarthy</surname><given-names>Mark</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Stockwell</surname><given-names>Amy D</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Maher</surname><given-names>Toby M</given-names></name><xref rid="A21" ref-type="aff">21</xref><xref rid="A22" ref-type="aff">22</xref></contrib><contrib contrib-type="author"><name><surname>Millar</surname><given-names>Ann B</given-names></name><xref rid="A23" ref-type="aff">23</xref></contrib><contrib contrib-type="author"><name><surname>Molyneaux</surname><given-names>Philip L</given-names></name><xref rid="A24" ref-type="aff">24</xref></contrib><contrib contrib-type="author"><name><surname>Molina-Molina</surname><given-names>Maria</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A25" ref-type="aff">25</xref><xref rid="A26" ref-type="aff">26</xref></contrib><contrib contrib-type="author"><name><surname>Navaratnam</surname><given-names>Vidya</given-names></name><xref rid="A27" ref-type="aff">27</xref><xref rid="A28" ref-type="aff">28</xref></contrib><contrib contrib-type="author"><name><surname>Neighbors</surname><given-names>Margaret</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Oldham</surname><given-names>Justin M</given-names></name><xref rid="A29" ref-type="aff">29</xref></contrib><contrib contrib-type="author"><name><surname>Parfrey</surname><given-names>Helen</given-names></name><xref rid="A30" ref-type="aff">30</xref></contrib><contrib contrib-type="author"><name><surname>Saini</surname><given-names>Gauri</given-names></name><xref rid="A15" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name><surname>Sayers</surname><given-names>Ian</given-names></name><xref rid="A11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>Rebecca Sheng</surname><given-names>X</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Stewart</surname><given-names>Iain D</given-names></name><xref rid="A31" ref-type="aff">31</xref></contrib><contrib contrib-type="author"><name><surname>Strek</surname><given-names>Mary E</given-names></name><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Tobin</surname><given-names>Martin D</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Whyte</surname><given-names>Moira KB</given-names></name><xref rid="A14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name><surname>Zarcone</surname><given-names>Maria C</given-names></name><xref rid="A21" ref-type="aff">21</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yingze</given-names></name><xref rid="A32" ref-type="aff">32</xref></contrib><contrib contrib-type="author"><name><surname>Martinez</surname><given-names>Fernando</given-names></name><xref rid="A8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Yaspan</surname><given-names>Brian L</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Reynolds</surname><given-names>Carl J</given-names></name><xref rid="A33" ref-type="aff">33</xref></contrib><contrib contrib-type="author"><name><surname>Schwartz</surname><given-names>David A</given-names></name><xref rid="A34" ref-type="aff">34</xref></contrib><contrib contrib-type="author"><name><surname>Flores</surname><given-names>Carlos</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="A18" ref-type="aff">18</xref><xref rid="A35" ref-type="aff">35</xref><xref rid="A36" ref-type="aff">36</xref></contrib><contrib contrib-type="author"><name><surname>Noth</surname><given-names>Imre</given-names></name><xref rid="A19" ref-type="aff">19</xref></contrib><contrib contrib-type="author"><name><surname>Gisli Jenkins</surname><given-names>R</given-names></name><xref rid="A21" ref-type="aff">21</xref></contrib><contrib contrib-type="author"><name><surname>Allen</surname><given-names>Richard J</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Wain</surname><given-names>Louise V</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Population Health Sciences, University of Leicester, Leicester, UK</aff><aff id="A2"><label>2</label>IHR Leicester Biomedical Research Centre, Leicester, UK</aff><aff id="A3"><label>3</label>Centre for Fibrosis Research, University of Leicester, Leicester, UK</aff><aff id="A4"><label>4</label>Genentech, California, USA</aff><aff id="A5"><label>5</label>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain</aff><aff id="A6"><label>6</label>University of Chicago, Chicago, USA</aff><aff id="A7"><label>7</label>University College London Hospitals, London, UK</aff><aff id="A8"><label>8</label>Weill Cornell Medicine, New York, USA</aff><aff id="A9"><label>9</label>GlaxoSmithKline, London, UK</aff><aff id="A10"><label>10</label>National Jewish Health, Colorado, USA</aff><aff id="A11"><label>11</label>Centre for Respiratory Research, NIHR Nottingham Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK</aff><aff id="A12"><label>12</label>University of Hull, Hull, UK</aff><aff id="A13"><label>13</label>University of Oxford, Oxford, UK</aff><aff id="A14"><label>14</label>University of Edinburgh, Edinburgh, UK</aff><aff id="A15"><label>15</label>University of Nottingham, Nottingham, UK</aff><aff id="A16"><label>16</label>Centre for Respiratory Research, NIHR Biomedical Research Centre and Biodiscovery Institute, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK</aff><aff id="A17"><label>17</label>Yale School of Medicine, Connecticut, USA</aff><aff id="A18"><label>18</label>Genomics Division, Instituto Tecnologico y de Energias Renovables, Santa Cruz de Tenerife, Spain</aff><aff id="A19"><label>19</label>University of Virginia, Virginia, USA</aff><aff id="A20"><label>20</label>University College London, London, UK</aff><aff id="A21"><label>21</label>NIHR Imperial Biomedical Research Unit, National Heart and Lung Institute, Imperial College London, London, UK</aff><aff id="A22"><label>22</label>Keck Medicine of USC, University of Southern California, Los Angeles, California, 90033, USA</aff><aff id="A23"><label>23</label>University of Bristol, Bristol, UK</aff><aff id="A24"><label>24</label>National Heart and Lung Institute, Imperial College London, London, UK</aff><aff id="A25"><label>25</label>Servei de Pneumologia, Hospital Universitari de Bellvitge (HUB), Laboratori de Pneumologia Experimental, Institut de Investigaci&#x000f3; Biom&#x000e8;dica de Bellvitge (IDIBELL), Barcelona, Spain</aff><aff id="A26"><label>26</label>Facultat de Medicine, Universitat de Barcelona, Barcelona, Spain</aff><aff id="A27"><label>27</label>Department of Respiratory Medicine, Sir Charles Gardiner Hospital, Perth, Australia</aff><aff id="A28"><label>28</label>Centre for Respiratory Research, University of Western Australia, Perth, Australia</aff><aff id="A29"><label>29</label>University of Michigan, Michigan, USA</aff><aff id="A30"><label>30</label>Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK</aff><aff id="A31"><label>31</label>Imperial College London, London, UK</aff><aff id="A32"><label>32</label>University of Pittsburgh, Pittsburgh, USA</aff><aff id="A33"><label>33</label>Imperial College, London, UK</aff><aff id="A34"><label>34</label>University of Colorado Medicine, Colorado, USA</aff><aff id="A35"><label>35</label>Research Unit, Hospital Universitario Nuestra Se&#x000f1;ora de Candelaria, Instituto de Investigaci&#x000f3;n Sanitaria de Canarias, Santa Cruz de Tenerife, Spain</aff><aff id="A36"><label>36</label>Facultad de Ciencias de la Salud, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain.</aff><author-notes><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">Contributed equally</p></fn><fn fn-type="con" id="FN2"><p id="P2">AUTHORS CONTRIBUTION</p><p id="P3">LVW and RJA designed and supervised the study. DPC, TH-B, LD, BG-G, and OCL performed the analyses. AA, HLB, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative, WAF, TEF, BG, IPH, SPH, MRH, NH, RBH, SJ, NK, JML-S, S-FM, RJM, MM, ADS, TMM, ABM, PLM, MM-M, VN, MN, JMO, HP, GS, IS, XRS, IDS, MES, MDT, MKBW, MCZ, YZ, FM, BLY, CJR, DAS, CF, IN, RGJ, and LVW participated in data collection. DPC, TH-B, and LVW wrote the first draft of the manuscript. All authors revised and approved the final version of the manuscript.</p></fn><corresp id="CR1"><bold>Corresponding author</bold>: Louise V. Wain, Department of Population Health Sciences, University of Leicester, UK, Leicester LE1 7RH, <email>lvw1@leicester.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>02</day><month>2</month><year>2025</year></pub-date><elocation-id>2025.01.30.25321017</elocation-id><permissions><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</ext-link>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.</license-p></license></permissions><self-uri content-type="pdf">nihpp-2025.01.30.25321017.pdf</self-uri><abstract id="ABS1"><sec id="S1"><title>Background</title><p id="P4">Idiopathic pulmonary fibrosis (IPF) is a rare, incurable lung disease with a median survival of 3&#x02013;5 years after diagnosis. Treatment options are limited. Genetic association studies can identify new genes involved in disease that might represent potential new drug targets, and it has been shown that drug targets with support from genetic studies are more likely to be successful in clinical development. Previous genome-wide association studies (GWAS) of IPF susceptibility have identified more than 20 signals implicating genes involved in multiple mechanisms, including telomere dysfunction, cell-cell adhesion, host defence immunity, various signalling pathways and, more recently, mitotic spindle assembly complex.</p></sec><sec id="S2"><title>Aim</title><p id="P5">To leverage new datasets and genotype imputation to discover further genes involved in development of IPF that could yield new pathobiological avenues for exploration and to guide future drug target discovery.</p></sec><sec id="S3"><title>Methods</title><p id="P6">We conducted a GWAS of IPF susceptibility including seven IPF case-control studies comprising 5,159 IPF cases and 27,459 controls of European ancestry, where IPF diagnosis was made by a respiratory clinician according to international guidelines. Genotypes were obtained from Whole Genome Sequencing (WGS) or from array-based imputation to the TOPMed WGS reference panel. New signals were replicated in independent biobanks with IPF defined using Electronic Healthcare Records. Bayesian fine-mapping was performed to identify the most likely causal variant(s) and bioinformatic investigation undertaken to map associated variants to putative causal genes.</p></sec><sec id="S4"><title>Results</title><p id="P7">We identified three novel genetic signals of association with IPF susceptibility. Genes prioritised by functional evidence at these signals included <italic toggle="yes">MUC1</italic>, which encodes a large transmembrane glycoprotein and known biomarker of lung fibrosis, and <italic toggle="yes">NTN4</italic> encoding Netrin-4 whose known roles include angiogenesis. The third signal may map to <italic toggle="yes">SLC6A6,</italic> a taurine and beta-alanine transporter gene, previously implicated in retinal, cardiac and kidney dysfunction.</p></sec><sec id="S5"><title>Conclusion</title><p id="P8">Our study has identified new associations not previously identified by previous large biobank-based studies thereby highlighting the value of utilising clinically-curated IPF case-control studies, and new genotype imputation. We present new evidence for disease-driving roles of <italic toggle="yes">MUC1</italic> and of endothelial cell and vascular changes in IPF.</p></sec></abstract><funding-group><award-group id="award01"><funding-source>Medical Research Council Programme Grant</funding-source><award-id>MR/V00235X/1</award-id></award-group><award-group id="award02"><funding-source>Wellcome Trust Genetic Epidemiology and Public Health Genomics Doctoral Training Programme</funding-source><award-id>218505/Z/19/Z</award-id></award-group><award-group id="award03"><funding-source>GlaxoSmithKline / Asthma + Lung UK Chair in Respiratory Research</funding-source><award-id>C17-1</award-id></award-group><award-group id="award04"><funding-source>Wellcome Trust</funding-source><award-id>221680/Z/20/Z</award-id></award-group><award-group id="award05"><funding-source>National Institutes of Health (NIH) National Heart, Lung, and Blood Institute</funding-source><award-id>R56HL158935</award-id><award-id>K23HL138190</award-id></award-group><award-group id="award06"><funding-source>Instituto de Salud Carlos III</funding-source><award-id>PI20/00876</award-id><award-id>PI23/00980</award-id><award-id>CB06/06/1088</award-id><award-id>PMP22/00083</award-id></award-group><award-group id="award07"><funding-source>European Regional Development Funds &#x0201c;A way of making Europe&#x0201d; from the EU, and by an agreement with Instituto Tecnol&#x000f3;gico y de Energ&#x000ed;as Renovables (ITER)</funding-source><award-id>OA23/043</award-id></award-group><award-group id="award08"><funding-source>Wellcome grant</funding-source><award-id>201291/Z/16/Z</award-id></award-group><award-group id="award09"><funding-source>National Institute for Health Research (NIHR) Leicester Biomedical Research Centre</funding-source></award-group><award-group id="award10"><funding-source>National Health Service, the NIHR, or the Department of Health</funding-source></award-group><award-group id="award11"><funding-source>ALICE and SPECTRE High Performance Computing Facility at the University of Leicester</funding-source></award-group></funding-group></article-meta></front><body><sec id="S6"><title>INTRODUCTION</title><p id="P9">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease thought to result from an aberrant response to lung injury, culminating in an exaggerated healing response with excessive deposition of extracellular matrix in the interstitium (<xref rid="R1" ref-type="bibr">1</xref>) (<xref rid="R2" ref-type="bibr">2</xref>). This incurable lung disease affects more than 7 in 100,000 people with poor survival (median survival of 3&#x02013;5 years after diagnosis) and has limited treatment options (<xref rid="R3" ref-type="bibr">3</xref>). IPF is incompletely understood and is significantly influenced by both genetic and environmental factors, with a high heritability and polygenic aetiology (<xref rid="R4" ref-type="bibr">4</xref>) (<xref rid="R5" ref-type="bibr">5</xref>).</p><p id="P10">Genome-wide association studies (GWAS) assess genetic variants from across the genome for their association with disease. Previous GWAS have highlighted more than 20 independent genetic signals linked to IPF susceptibility, implicating pathways such as telomere dysfunction, cell-cell adhesion, host defence, TGF-&#x003b2; signalling, and mitotic spindle assembly (<xref rid="R4" ref-type="bibr">4</xref>) (<xref rid="R6" ref-type="bibr">6</xref>) (<xref rid="R7" ref-type="bibr">7</xref>) (<xref rid="R8" ref-type="bibr">8</xref>) (<xref rid="R9" ref-type="bibr">9</xref>) (<xref rid="R10" ref-type="bibr">10</xref>). Whole genome sequencing (WGS) technologies provide comprehensive genomic coverage, but remain cost prohibitive for large studies. Instead, reference panels derived from large WGS datasets allow for improved imputation of unmeasured variants, including those with low allele frequencies, providing a cost-effective solution for increased genome-wide coverage (<xref rid="R11" ref-type="bibr">11</xref>).</p><p id="P11">Although each genetic signal has a small individual effect, except for the gain-of-function <italic toggle="yes">MUC5B</italic> promoter variant (<xref rid="R5" ref-type="bibr">5</xref>)(<xref rid="R12" ref-type="bibr">12</xref>), targeting the pathways conferred by genetic associations could offer significant therapeutic potential, as drug targets supported by genetic evidence studies have a higher likelihood of success in clinical development (<xref rid="R13" ref-type="bibr">13</xref>). This is driving efforts to increase the discovery of IPF-associated genes and to refine existing signals to identify the most likely causal variants molecular and mechanistic evaluation.</p><p id="P12">For this study, we re-imputed previously published studies using a more recent imputation panel that enables measurement of three times as many variants as our previous studies and aggregated new datasets comprising clinically-curated IPF cases, and controls, to improve the quality and coverage of genotyping and to increase sample size for new gene discovery while offering more precise risk estimates. Our findings implicate new loci for IPF susceptibility.</p></sec><sec id="S7"><title>METHODS</title><sec id="S8"><title>Datasets</title><p id="P13">Seven independent case&#x02013;control studies were analysed: Colorado (<xref rid="R14" ref-type="bibr">14</xref>), US (<xref rid="R8" ref-type="bibr">8</xref>), UK (<xref rid="R9" ref-type="bibr">9</xref>), IPF Job Exposures Study (IPF-JES) (<xref rid="R15" ref-type="bibr">15</xref>), Genentech (<xref rid="R16" ref-type="bibr">16</xref>), United States, United Kingdom, and Spain (UUS) (<xref rid="R10" ref-type="bibr">10</xref>) and Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis - University of California, Davis (CleanUP-UCD) (<xref rid="R17" ref-type="bibr">17</xref>) datasets (<xref rid="F1" ref-type="fig">Figure 1</xref>). All studies included unrelated European-ancestry individuals, with cases of IPF diagnosed according to the American Thoracic Society and European Respiratory Society guidelines (<xref rid="R18" ref-type="bibr">18</xref>)(<xref rid="R19" ref-type="bibr">19</xref>)(<xref rid="R20" ref-type="bibr">20</xref>). Written informed consent and ethics approval were properly obtained for all studies, following the World Medical Association&#x02019;s Code of Ethics (Declaration of Helsinki) and approved by the appropriate institutional review board or Research Ethics Committee. More information on each study can be found in the <xref rid="SD1" ref-type="supplementary-material">supplementary material</xref>.</p></sec><sec id="S9"><title>Genotyping and quality controls</title><p id="P14">The Colorado, IPF-JES, UK, US, UUS, and CleanUP-UCD studies had been genotyped using SNP arrays (<xref rid="SD1" ref-type="supplementary-material">supplementary material</xref>). Quality control measures included filtering for low call rates, sex mismatches, heterozygosity, non-European genetic ancestry, relatedness, and ensuring no overlap between studies. These six studies were imputed using the TOPMed WGS reference panel (GRCh38) via the TOPMed Imputation Server (<xref rid="R21" ref-type="bibr">21</xref>). For the Genentech study, genotypes were obtained through WGS on the Illumina HiSeq X Ten platform with an average read depth of 30X. Related individuals and those with call rates below 10% were excluded from the analysis. Additional details are available in previously published studies (<xref rid="R14" ref-type="bibr">14</xref>), (<xref rid="R8" ref-type="bibr">8</xref>), (<xref rid="R9" ref-type="bibr">9</xref>), (<xref rid="R15" ref-type="bibr">15</xref>), (<xref rid="R16" ref-type="bibr">16</xref>), (<xref rid="R10" ref-type="bibr">10</xref>) (<xref rid="R17" ref-type="bibr">17</xref>) and the <xref rid="SD1" ref-type="supplementary-material">supplementary material</xref>.</p></sec><sec id="S10"><title>Association analysis and meta-analysis</title><p id="P15">For six studies (Colorado, IPF-JES, UK, US, UUS, and CleanUP-UCD), genome-wide association analyses were conducted using logistic regression with PLINK v2 (<xref rid="R22" ref-type="bibr">22</xref>) adjusting each study for the first ten principal components to correct for population stratification. Variants with a poor imputation quality (r2&#x0003c;0.5) and minor allele count (MAC) &#x02264;3 were removed. Association analysis for the Genentech study was performed using logistic regression with PLINK v1.9 (<xref rid="R22" ref-type="bibr">22</xref>) including sex, age, and five genetic-ancestry principal components as covariates.</p><p id="P16">The seven datasets were meta-analysed using inverse-variance weighted fixed effects meta-analysis using METAL (<xref rid="R23" ref-type="bibr">23</xref>), excluding variants that did not pass quality control in at least two studies. No minor allele frequency filter was applied. We estimated the genomic inflation factor using LDSC (<xref rid="R24" ref-type="bibr">24</xref>), and we applied a correction when this factor exceeded 1.10 in the meta-analysis. Data for chromosome X were available for four studies (UUS, Colorado, CleanUP-UCD, and UK) with GWAS and meta-analysis performed as described above (see <xref rid="SD1" ref-type="supplementary-material">supplementary material</xref>). For chromosome X, we applied a correction when classic lambda factor exceeded 1.15 in the meta-analysis.</p></sec><sec id="S11"><title>Signal selection</title><p id="P17">Independent association signals were selected after performing conditional analysis with COJO-GCTA v1.90.2 (<xref rid="R25" ref-type="bibr">25</xref>), and based on a <italic toggle="yes">p</italic> value threshold of &#x0003c;5.0&#x000d7;10<sup>&#x02212;8</sup>. Forest plots were prepared using the forestplot R v4.1.3 package and visually reviewed for outlying study signals. Signals were excluded if the significance (<italic toggle="yes">p</italic> value) of the association in any individual study was lower than the meta-analysis significance (i.e., if combining data across studies served to reduce the association rather than support it). We sought replication of new signals using an independent subset of the Global Biobank Meta-analysis Initiative (GBMI) IPF GWAS (<xref rid="R26" ref-type="bibr">26</xref>) comprising 6,257 cases defined using Electronic Healthcare Records (EHR), and 947,616 controls, all of European ancestry. We defined a replication threshold of <italic toggle="yes">p</italic>&#x0003c;0.05 with Bonferroni correction for the number of new signals tested. We annotated the sentinel variants with ANNOVAR v07.06.20 (<xref rid="R27" ref-type="bibr">27</xref>) and Ensembl Variant Effect Predictor (VEP) v.105, and we identified potentially causal variants using the Wakefield Bayes factor method to calculate the posterior inclusion probability (PIP) of each variant to define a 95% credible set (<xref rid="R28" ref-type="bibr">28</xref>). We performed look-ups for all SNPs previously reported for association with IPF at genome-wide significance (<italic toggle="yes">p</italic>&#x0003c;5&#x000d7;10<sup>&#x02212;8</sup>).</p></sec><sec id="S12"><title><italic toggle="yes">In silico</italic> functional assessment</title><p id="P18">We performed a comprehensive functional impact assessment using empirical data from several integrated software tools and datasets for the sentinel SNPs and for each variant in the credible set with a PIP&#x0003e;0.1. We interrogated gene expression Quantitative Trait Locus (eQTLs) from the Genotype-Tissue Expression Project (GTEx) v8 (<xref rid="R29" ref-type="bibr">29</xref>) to identify whether IPF variants were associated with expression of any genes in lung, cultured fibroblasts or whole blood (see <xref rid="SD1" ref-type="supplementary-material">supplementary material</xref> for further details). We used coloc (<xref rid="R30" ref-type="bibr">30</xref>) R v4.1.3 package to investigate whether the same causal variant was driving both the genetic association with IPF risk and an association with gene expression changes and report shared signals with a colocalisation probability hypothesis 4 (H4) &#x0003e;0.7. We functionally annotated the highlighted regions based on active chromatin marks (i.e., DHS, eRNAs, ATACseq, CHIPseq, H3K27ac) (<xref rid="R31" ref-type="bibr">31</xref>) and searched for mouse orthologs of the human genes where knockout resulted in a measurable respiratory phenotype (<ext-link xlink:href="https://www.mousephenotype.org/" ext-link-type="uri">https://www.mousephenotype.org/</ext-link>). We used Open Targets Genetics to identify additional supporting data for variant to gene mapping and for phenome-wide association study (PheWAS) analysis.</p></sec></sec><sec id="S13"><title>RESULTS</title><p id="P19">We analysed 5,159 IPF cases and 27,459 controls of European ancestry, and a total of 25,290,839 autosomal variants (<xref rid="F2" ref-type="fig">Figure 2</xref> &#x00026; <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>). For X chromosome, association analyses were performed for 23,890 individuals (3,388 IPF cases and 20,502 controls), and 262,089 variants. There was no evidence of inflated test statistics (<xref rid="F2" ref-type="fig">Figure 2</xref> &#x00026; <xref rid="SD1" ref-type="supplementary-material">Figure S1</xref>). After conditional analyses, we identified 37 autosomal independent significant signals (<italic toggle="yes">p</italic>&#x0003c;5&#x000d7;10<sup>&#x02212;8</sup>), three of which were supported by multiple studies and had not been previously reported (<xref rid="T1" ref-type="table">Table 1</xref> &#x00026; <xref rid="F3" ref-type="fig">Figure 3</xref>). All three signals were replicated in the independent GBMI IPF GWAS (<italic toggle="yes">p</italic>&#x0003c;0.0125 (<xref rid="T1" ref-type="table">Table 1</xref>). Only one signal (3p25.1) included a single SNP that accounted for more than 50% of the posterior probability of being causal (rs112271207 PIP=0.691) (<xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). All signals overlapped open chromatin marks/regions (ATACseq or DHS) with evidence of enhancer activity (CHIPseq: H3K27ac) (<xref rid="T2" ref-type="table">Table 2</xref> &#x00026; <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>). No signals reached the genome-wide significance threshold for the X chromosome analysis.</p><p id="P20">There were 32 previously reported IPF susceptibility signals and 31 were represented by variants in our dataset (<xref rid="SD1" ref-type="supplementary-material">Table S4</xref>) (an intronic signal, rs539683219, in the <italic toggle="yes">PSKH1</italic> gene could not be assessed and had previously been shown to be unique to East Asian ancestry populations (<xref rid="R6" ref-type="bibr">6</xref>)). All but three signals (in or near <italic toggle="yes">DNAJB4</italic>, <italic toggle="yes">FSTL5</italic> and <italic toggle="yes">TPI1P2</italic>) met a Bonferroni-corrected threshold of <italic toggle="yes">p</italic>&#x0003c;1.56&#x000d7;10<sup>&#x02212;3</sup> in our study and all but seven signals reached genome-wide significance. These seven included five previously reported association signals (in or near <italic toggle="yes">DNAJB4, FSTL5, TPI1P2, GPR157</italic>, and <italic toggle="yes">FKBP5</italic>) whose initial discovery had been enabled by a multi-ancestry study design) (<xref rid="R6" ref-type="bibr">6</xref>) and two signals (at 10q25.1 and <italic toggle="yes">STMN3</italic>) previously reported in a meta-analysis of a subset of the studies included here (<xref rid="R4" ref-type="bibr">4</xref>).</p><p id="P21">The most statistically significant new signal (rs112271207, 3p25.1) was a common (MAF 6%) intergenic variant located 91.6 kb downstream of <italic toggle="yes">LSM3</italic> and 77.6 kb upstream of <italic toggle="yes">LINC01267</italic>. This SNP had previously been associated at near-genome-wide significance with lung function (<italic toggle="yes">p</italic>=6.1&#x000d7;10<sup>&#x02212;8</sup>) with the allele associated with increased risk of IPF (T) associated with decreased lung function. The variant was not associated with gene expression in GTEx. The Open Targets Genetics V2G annotation prioritised a member of a family of sodium and chloride ion dependent transporters (<italic toggle="yes">SLC6A6)</italic> (132 kb downstream) as the most likely causal gene based on chromatin interaction data (<xref rid="SD1" ref-type="supplementary-material">Table S3</xref>).</p><p id="P22">The second most significant signal (rs9426886, 1q22) was located within an intron of the <italic toggle="yes">TRIM46</italic> gene, which is involved in the formation of parallel microtubule bundles. Although the sentinel variant was significantly associated with expression of several genes in cultured fibroblast, lung and whole blood (<xref rid="SD1" ref-type="supplementary-material">Table S5</xref>), the highest colocalisation probability was 0.616 for <italic toggle="yes">MUC1</italic> in whole blood. <italic toggle="yes">MUC1</italic> encodes a cell-surface glycoprotein. The IPF risk allele (T) associated with increased expression of <italic toggle="yes">MUC1</italic> in whole blood. This signal was also associated with urate levels (<italic toggle="yes">p</italic>=1.5&#x000d7;10<sup>&#x02212;101</sup>) and haematocrit measurement (<italic toggle="yes">p</italic>=4.7&#x000d7;10<sup>&#x02212;41</sup>) with the allele associated with increased IPF risk associated with increased haematocrit measurement, and decreased urate levels.</p><p id="P23">Finally, the signal at 12q23.1 (rs7957346) had the highest probability of colocalisation for expression of Netrin 4 (<italic toggle="yes">NTN4</italic>) in lung tissue (posterior probability = 0.649) and had previously been associated with lung function with the IPF risk increasing allele (A) associated with decreased lung function (<italic toggle="yes">p</italic>=7.8&#x000d7;10<sup>&#x02212;45</sup>). <italic toggle="yes">NTN4</italic> encodes Netrin 4; netrins are a family of proteins involved in cell and axon migration during development and link to angiogenesis and vascularization.</p></sec><sec id="S14"><title>DISCUSSION</title><p id="P24">Using our large clinically-curated IPF case-control resources, together with new imputation to the TOPMed Reference panel, we report novel associations that extend our previous genetic findings for IPF susceptibility and implicate new genes involved in its pathobiology.</p><p id="P25">All of the studies included in the genome-wide discovery stage of this analysis comprised cases that have been defined according to clinical criteria. Previous studies have noted an attenuation of effect sizes for IPF risk associated variants in studies where IPF case status has been defined using routine EHR (<xref rid="R6" ref-type="bibr">6</xref>)(<xref rid="R32" ref-type="bibr">32</xref>). Despite a smaller discovery sample size than previous studies that included IPF cases defined by EHR, we identified new signals that were replicated in an independent biobank EHR-based dataset (<xref rid="R6" ref-type="bibr">6</xref>). The use of the TOPMed Imputation reference panel enabled us to analyse over 25 million variants with a minor allele count greater than 3 and imputation quality greater than 0.5. This represented a more than 3-fold increase in variants analysed over our previous clinically-curated IPF GWAS (<xref rid="R4" ref-type="bibr">4</xref>). Accounting for a larger number of variants tested, two of our three new signals would have exceeded a more stringent genome-wide significance threshold of <italic toggle="yes">p</italic>&#x0003c;5&#x000d7;10<sup>&#x02212;9</sup> in our discovery GWAS and the third would also have exceeded this threshold had we applied a two-stage design with meta-analysis of discovery GWAS and replication data. Nevertheless, the consistency of the signals across the participating studies (including replication) provides reassurance on the robust nature of the signals.</p><p id="P26">The signal at 1q22 suggestively implicated <italic toggle="yes">MUC1</italic> which encodes a cell surface glycoprotein well known to be important in several lung diseases and infections (<xref rid="R33" ref-type="bibr">33</xref>). The MUC1 glycoprotein comprises three domains; an extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain becomes cleaved during alveolar epithelial damage and is commonly known as Krebs Von Den Lungen-6 (KL-6)<italic toggle="yes">.</italic> KL-6 has been widely recognised as a potential prognostic biomarker of lung fibrosis as it is elevated in the serum and bronchioalveolar lavage fluid of patients with IPF. Studies have shown that KL-6 may also drive fibrosis through promotion of fibroblast activation and their differentiation to myofibroblasts. The MUC1 cytoplasmic tail (CT) has also been implicated in intracellular signalling in fibrosis (<xref rid="R34" ref-type="bibr">34</xref>). The biology of MUC1 is complex, however, early trials in cancer, where MUC1 is a well-studied tumour-associated antigen, suggest that monoclonal antibodies or inhibitors of MUC1 might represent a new therapeutic avenue for IPF (<xref rid="R35" ref-type="bibr">35</xref>). Although the highest colocalisation probability implicated <italic toggle="yes">MUC1</italic>, the evidence was from blood only, and we cannot not rule out the possibility that another nearby gene might be the true causal gene for this locus. Of particular note, thrombospondin-3 (<italic toggle="yes">THBS3</italic>) has a known role in cell-to-cell and cell-to-matrix interactions and has been implicated in cardiac fibrosis (<xref rid="R36" ref-type="bibr">36</xref>) and skin healing (<xref rid="R37" ref-type="bibr">37</xref>).</p><p id="P27">The signal on chromosome 12, overlapping the 3&#x02019;-UTR of <italic toggle="yes">SNRPF</italic>, provided the strongest colocalisation with gene expression evidence in this study for <italic toggle="yes">NTN4</italic> which encodes the secreted protein Netrin-4, originally identified as a guide of axon migration but more recently established to have an important role in kidney and vascular development, and has also been implicated in lung morphogenesis (<xref rid="R38" ref-type="bibr">38</xref>). <italic toggle="yes">NTN4</italic> is relatively highly expressed in aberrant basaloid cells (<ext-link xlink:href="https://IPFCellAtlas.com" ext-link-type="uri">IPFCellAtlas.com</ext-link>; (<xref rid="R39" ref-type="bibr">39</xref>)), a recently described patient-specific cell population (<xref rid="R40" ref-type="bibr">40</xref>)(<xref rid="R41" ref-type="bibr">41</xref>)(<xref rid="R42" ref-type="bibr">42</xref>). <italic toggle="yes">NTN4</italic> has also been implicated by GWAS of diffusing capacity for carbon monoxide (DLCO) in a population enriched for COPD patients (<xref rid="R43" ref-type="bibr">43</xref>). The role of Netrin-4 in angiogenesis (<xref rid="R44" ref-type="bibr">44</xref>)(<xref rid="R45" ref-type="bibr">45</xref>)(<xref rid="R46" ref-type="bibr">46</xref>) and the renewed interest in the relevance of endothelial cell and vascular abnormalities in IPF (<xref rid="R47" ref-type="bibr">47</xref>) make this an intriguing signal for further investigation. Previous genetic association studies of other respiratory traits have also implicated Small Nuclear Ribonucleoprotein Polypeptide F (<italic toggle="yes">SNRPF</italic>) (<xref rid="R48" ref-type="bibr">48</xref>)(<xref rid="R49" ref-type="bibr">49</xref>) and centrosome gene, <italic toggle="yes">CCDC38</italic> (<xref rid="R50" ref-type="bibr">50</xref>) at this locus.</p><p id="P28">The most significant new signal (<italic toggle="yes">p</italic>=2.23&#x000d7;10<sup>&#x02212;11</sup>) was located near to <italic toggle="yes">LSM3</italic>, encoding &#x02018;LSM3 Homolog, U6 Small Nuclear RNA And MRNA Degradation Associated&#x02019;, an sm-like protein with roles in RNA metabolism. The variant also mapped to <italic toggle="yes">SLC6A6,</italic> a taurine and beta-alanine transporter gene, implicated in Hypotaurinemic Retinal Degeneration and Cardiomyopathy (HTRDC) (<xref rid="R51" ref-type="bibr">51</xref>) and kidney fibrosis in diabetic knockout mice (<xref rid="R52" ref-type="bibr">52</xref>). Taurine may have a role in lung homeostasis and protection against oxidative stress (<xref rid="R53" ref-type="bibr">53</xref>)(<xref rid="R54" ref-type="bibr">54</xref>), a known driver of IPF pathogenesis.</p><p id="P29">A key challenge in translating genetic association signals to mechanistic insight is robust variant-to-gene mapping to understand the functional, and ultimately clinical, consequence of the genetic perturbation (<xref rid="R55" ref-type="bibr">55</xref>). We applied several <italic toggle="yes">in silico</italic> approaches to map the associated signals to genes. However, none of our signals included either a gene coding region or splice elements or had a high probability of sharing a causal variant with an eQTL for nearby genes. Additional functional <italic toggle="yes">in silico</italic> approaches, as well as <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies are needed to map these new signals to genes, predict their function, and investigate their biological function and relevance to IPF.</p><p id="P30">Our study only included individuals of European ancestry which means that we cannot assess the generalisability of these association signals to other populations. We were unable to validate several previously reported signals that had been reported in multi-ancestry studies. There is a dearth of studies of clinically-curated IPF case-control datasets; these prior multi-ancestry studies were predominantly derived from large population biobanks. Future efforts should be focused on increasing availability of carefully phenotyped IPF datasets from non-European ancestry populations.</p><p id="P31">In conclusion, we have identified new signals of association with IPF risk that may provide further mechanistic insight into the pathobiology of IPF and support identification of potential new drug targets.</p></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data"><label>Supplement 1</label><media xlink:href="media-1.pdf" id="d67e1113" position="anchor"/></supplementary-material></sec></body><back><ack id="S15"><title>FUNDING</title><p id="P32">This study was funded by a Medical Research Council Programme Grant (MR/V00235X/1) to RGJ and LVW by a Wellcome Trust PhD studentship for DC as part of the Wellcome Trust Genetic Epidemiology and Public Health Genomics Doctoral Training Programme (218505/Z/19/Z). LVW held a GlaxoSmithKline / Asthma + Lung UK Chair in Respiratory Research (C17&#x02013;1). BGG is supported by Wellcome Trust grant 221680/Z/20/Z. JMO reports National Institutes of Health (NIH) National Heart, Lung, and Blood Institute grants R56HL158935 and K23HL138190. CF is supported by the Instituto de Salud Carlos III (PI20/00876, PI23/00980, CB06/06/1088, and PMP22/00083), co-financed by the European Regional Development Funds &#x0201c;A way of making Europe&#x0201d; from the EU, and by an agreement with Instituto Tecnol&#x000f3;gico y de Energ&#x000ed;as Renovables (ITER) to strengthen scientific and technological education, training, research, development and innovation in genomics, epidemiological surveillance based on massive sequencing, personalized medicine, and biotechnology (OA23/043). CJR was supported by Wellcome grant 201291/Z/16/Z. This work was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service, the NIHR, or the Department of Health. This research used the ALICE and SPECTRE High Performance Computing Facility at the University of Leicester. For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</p></ack><fn-group><fn fn-type="COI-statement" id="FN3"><p id="P34">COMPETING INTERESTS</p><p id="P35">LD is full-time employee of Genentech. AS hold stock options in Genentech. MN is full time employee of Genentech, Inc., a wholly owned subsidiary of Roche, and from which entity the data was sourced without fee/requirement. XRS, MM and BLY are full-time employees of Genentech and hold stock options in Roche. WAF is full-time employee of GSK. JMO reports personal fees from Boehringer Ingelheim, Genentech, United Therapeutics, AmMax Bio and Lupin Pharmaceuticals outside of the submitted work. DAS is a consultant for Vertex and the founder and chief scientific officer of Eleven P15, a company focused on the early detection and treatment of pulmonary fibrosis. BG has received in-kind research support from Galecto Biotech, and consultancy honoraria from GSK. AA reports personal fees from Boehringer Ingelheim, Genentech, Medscape, Abbvie, PatientMpower, Brainomix, PureTech, Gossamer Bio and Inogen outside of the submitted work. MES reports research funding from Boehringer Ingelheim, consultancy for Boehringer Ingelheim, and participation on Adjudication Committee or Data Safety Board for Bristol Myers Squibb, Fibrinogen and Pliant. SH reports payment from Trevi therapeutics, Boehringer Ingelheim, and Chiesi. SJ reports payment from Boehringer Ingelheim. TMM reports personal fees from Boehringer Ingelheim, Roche/Genentech, Abbvie, Amgen, Astra Zeneca, Bayer, Bridge bio, Bristol-Myers Squibb, CSL Behring, Galapagos, Galecto, GSK, IQVIA, Merck, Pfizer, Pliant, PureTech, Sanofi, Trevi, Vicore; and participation in Fibrogen, United Therapeutics and Nerre. IN reports personal fees from Boehringer Ingelheim and Sanofi. HP reports personal fees from Boehringher Ingelheim Ltd and Trevi Therapeutics. PLM reports advisory board fees from Hoffman-La Roche, Boehringer Ingelheim, AstraZeneca, Trevi, Qureight, Endevour; and personal fees from United Therapeutics. MDT reports respiratory Drug Delivery 2023 speaker fee, unrelated to the manuscript. MM-M reports payment from Boehringer Ing, Ferrer, and Chiesi. FM reports consulting but no fees from AstraZeneca, Boehringer Ingelheim, Excalibur, GSK, Hoffmann-LaRoche, Lung Therapeutics, RS Biotherapeutics, Two XR; and travel expenses paid by Boehringer Ingelheim. CF declares funding Ministerio de Ciencia e Innovaci&#x000f3;n, Instituto de Salud Carlos III and Instituto Tecnol&#x000f3;gico y de Energ&#x000ed;as Renovables; honoraria in educational events from Fundaci&#x000f3;n Instituto Roche. RGJ reports honoraria from Chiesi, Roche, PatientMPower, AstraZeneca, GSK, Boehringer Ingelheim, and consulting fees from AdAlta, Abbvie, Arda Therapeutics, Bristol Myers Squibb, Veracyte, RedX, Pliant, Chiesi. LVW reports research funding from GlaxoSmithKline, Roche and Orion Pharma, and consultancy for GlaxoSmithKline and Galapagos, outside of the submitted work. The other authors declare no competing interests.</p></fn><fn id="FN4"><p id="P36">ETHICS</p><p id="P37">This research was conducted with appropriate ethics approval. The PROFILE study (which provided samples for the UK and UUS studies) had institutional ethics approval at the University of Nottingham (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01134822" ext-link-type="uri">NCT01134822</ext-link> - ethics reference 10/H0402/2) and Royal Brompton and Harefield NHS Foundation Trust (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01110694" ext-link-type="uri">NCT01110694</ext-link> - ethics reference 10/H0720/12). UK samples were recruited across multiple sites with individual ethics approval (University of Edinburgh Research Ethics Committee [The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04016181" ext-link-type="uri">NCT04016181</ext-link>] 17/ES/0075, NRES Committee South West - Southmead, Yorkshire and Humber Research Ethics Committee 08/H1304/54 and Nottingham Research Ethics Committee 09/H0403/59). Spanish samples were recruited under ethics approval by ethics committee from the Hospital Universitario N.S. de Candelaria (reference of the approval: PI-19/12). The UUS study also included individuals from clinical trials with ethics approval (ACE [<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00957242" ext-link-type="uri">NCT00957242</ext-link>] and PANTHER [<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00650091" ext-link-type="uri">NCT00650091</ext-link>]). For the UCSF cohort, sample and data collection were approved by the University of California San Francisco Committee on Human Research and all patients provided written informed consent. For the Vanderbilt cohort, the Institutional Review Boards from Vanderbilt University approved the study and all participants provided written informed consent before enrolment. For individuals recruited at the University of Chicago, consenting patients with IPF who were prospectively enrolled in the institutional review board-approved ILD registry (IRB#14163A) were included. Individuals recruited at the University of Pittsburgh Medical Centre had ethics approval from the University of Pittsburgh Human Research Protection Office (referenceSTUDY20030223: Genetic Polymorphisms in IPF). Individuals from the COMET (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01071707" ext-link-type="uri">NCT01071707</ext-link>) and Lung Tissue Research Consortium (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02988388" ext-link-type="uri">NCT02988388</ext-link>) studies were also included in the Chicago study. All subjects in the Colorado study gave written informed consent as part of IRB-approved protocols for their recruitment at each site and the GWAS study was approved by the National Jewish Health IRB and Colorado Combined Institutional Review Boards (COMIRB). Subjects in the Genentech study provided written informed consent for whole-genome sequencing of their DNA. Ethical approval was provided as per the original clinical trials (INSPIRE [<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00075998" ext-link-type="uri">NCT00075998</ext-link>], RIFF [<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01872689" ext-link-type="uri">NCT01872689</ext-link>], CAPACITY [<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00287729" ext-link-type="uri">NCT00287729</ext-link> and <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT00287716" ext-link-type="uri">NCT00287716</ext-link>] and ASCEND [<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01366209" ext-link-type="uri">NCT01366209</ext-link>]). Individuals in the CleanUP-UCD study included individuals from clinical trials with ethics approval (<ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02759120" ext-link-type="uri">NCT02759120</ext-link>). These samples were genotyped under University of Virginia ethics approval (IRB 20845). IPFJES involved human participants and was approved by East Midlands - Nottingham 1 Research Ethics Committee REC reference: 17/EM/0021IRAS project ID: 203355. Participants gave informed consent to participate in the study before taking part.</p></fn></fn-group><sec sec-type="data-availability" id="S28"><title>DATA AVAILABILITY</title><p id="P33">Summary statistics (i.e., effect size estimates, standard errors, <italic toggle="yes">p</italic> values and basic variant information) for all variants included in the genome-wide meta-analysis can be accessed via <ext-link xlink:href="https://github.com/genomicsITER/PFgenetics" ext-link-type="uri">https://github.com/genomicsITER/PFgenetics</ext-link>.</p></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Undurraga</surname><given-names>&#x000c1;.</given-names></name>
<article-title>Fibrosis pulmonar idiop&#x000e1;tica</article-title>. <source>Revista m&#x000e9;dica cl&#x000ed;nica las Condes</source>. <year>2015</year>;<volume>26</volume>(<issue>3</issue>):<fpage>292</fpage>&#x02013;<lpage>301</lpage>.</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Lederer</surname><given-names>DJ</given-names></name>, <name><surname>Martinez</surname><given-names>FJ</given-names></name>. <article-title>Idiopathic pulmonary fibrosis</article-title>. <source>N Engl J Med</source>. <year>2018</year>;<volume>378</volume>(<issue>19</issue>):<fpage>1811</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">29742380</pub-id>
</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Gupta</surname><given-names>RS</given-names></name>, <name><surname>Koteci</surname><given-names>A</given-names></name>, <name><surname>Morgan</surname><given-names>A</given-names></name>, <name><surname>George</surname><given-names>PM</given-names></name>, <name><surname>Quint</surname><given-names>JK</given-names></name>. <article-title>Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review</article-title>. <source>BMJ Open Respiratory Research</source>. <year>2023</year>;<volume>10</volume>(<issue>1</issue>):<fpage>e001291</fpage>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>RJ</given-names></name>, <name><surname>Stockwell</surname><given-names>A</given-names></name>, <name><surname>Oldham</surname><given-names>JM</given-names></name>, <name><surname>Guillen-Guio</surname><given-names>B</given-names></name>, <name><surname>Schwartz</surname><given-names>DA</given-names></name>, <name><surname>Maher</surname><given-names>TM</given-names></name>, <etal/>
<article-title>Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis</article-title>. <source>Thorax</source>. <year>2022</year>;<volume>77</volume>(<issue>8</issue>):<fpage>829</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">35688625</pub-id>
</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Peljto</surname><given-names>AL</given-names></name>, <name><surname>Blumhagen</surname><given-names>RZ</given-names></name>, <name><surname>Walts</surname><given-names>AD</given-names></name>, <name><surname>Cardwell</surname><given-names>J</given-names></name>, <name><surname>Powers</surname><given-names>J</given-names></name>, <name><surname>Corte</surname><given-names>TJ</given-names></name>, <etal/>
<article-title>Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2023</year>;<volume>207</volume>(<issue>9</issue>):<fpage>1194</fpage>&#x02013;<lpage>202</lpage>.<pub-id pub-id-type="pmid">36602845</pub-id>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Partanen</surname><given-names>JJ</given-names></name>, <name><surname>H&#x000e4;pp&#x000f6;l&#x000e4;</surname><given-names>P</given-names></name>, <name><surname>Zhou</surname><given-names>W</given-names></name>, <name><surname>Lehisto</surname><given-names>AA</given-names></name>, <name><surname>Ainola</surname><given-names>M</given-names></name>, <name><surname>Sutinen</surname><given-names>E</given-names></name>, <etal/>
<article-title>Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics</article-title>. <source>Cell genomics</source>. <year>2022</year>;<volume>2</volume>(<issue>10</issue>).</mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Mushiroda</surname><given-names>T</given-names></name>, <name><surname>Wattanapokayakit</surname><given-names>S</given-names></name>, <name><surname>Takahashi</surname><given-names>A</given-names></name>, <name><surname>Nukiwa</surname><given-names>T</given-names></name>, <name><surname>Kudoh</surname><given-names>S</given-names></name>, <name><surname>Ogura</surname><given-names>T</given-names></name>, <etal/>
<article-title>A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis</article-title>. <source>J Med Genet</source>. <year>2008</year>;<volume>45</volume>(<issue>10</issue>):<fpage>654</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">18835860</pub-id>
</mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Noth</surname><given-names>I</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Ma</surname><given-names>S</given-names></name>, <name><surname>Flores</surname><given-names>C</given-names></name>, <name><surname>Barber</surname><given-names>M</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <etal/>
<article-title>Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study</article-title>. <source>The Lancet respiratory medicine</source>. <year>2013</year>;<volume>1</volume>(<issue>4</issue>):<fpage>309</fpage>&#x02013;<lpage>17</lpage>.<pub-id pub-id-type="pmid">24429156</pub-id>
</mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>RJ</given-names></name>, <name><surname>Porte</surname><given-names>J</given-names></name>, <name><surname>Braybrooke</surname><given-names>R</given-names></name>, <name><surname>Flores</surname><given-names>C</given-names></name>, <name><surname>Fingerlin</surname><given-names>TE</given-names></name>, <name><surname>Oldham</surname><given-names>JM</given-names></name>, <etal/>
<article-title>Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study</article-title>. <source>The Lancet respiratory medicine</source>. <year>2017</year>;<volume>5</volume>(<issue>11</issue>):<fpage>869</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="pmid">29066090</pub-id>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Allen</surname><given-names>RJ</given-names></name>, <name><surname>Guillen-Guio</surname><given-names>B</given-names></name>, <name><surname>Oldham</surname><given-names>JM</given-names></name>, <name><surname>Ma</surname><given-names>S</given-names></name>, <name><surname>Dressen</surname><given-names>A</given-names></name>, <name><surname>Paynton</surname><given-names>ML</given-names></name>, <etal/>
<article-title>Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2020</year>;<volume>201</volume>(<issue>5</issue>):<fpage>564</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">31710517</pub-id>
</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Taliun</surname><given-names>D</given-names></name>, <name><surname>Harris</surname><given-names>DN</given-names></name>, <name><surname>Kessler</surname><given-names>MD</given-names></name>, <name><surname>Carlson</surname><given-names>J</given-names></name>, <name><surname>Szpiech</surname><given-names>ZA</given-names></name>, <name><surname>Torres</surname><given-names>R</given-names></name>, <etal/>
<article-title>Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program</article-title>. <source>Nature</source>. <year>2021</year>;<volume>590</volume>(<issue>7845</issue>):<fpage>290</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">33568819</pub-id>
</mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Seibold</surname><given-names>MA</given-names></name>, <name><surname>Wise</surname><given-names>AL</given-names></name>, <name><surname>Speer</surname><given-names>MC</given-names></name>, <name><surname>Steele</surname><given-names>MP</given-names></name>, <name><surname>Brown</surname><given-names>KK</given-names></name>, <name><surname>Loyd</surname><given-names>JE</given-names></name>, <etal/>
<article-title>A common MUC5B promoter polymorphism and pulmonary fibrosis</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>(<issue>16</issue>):<fpage>1503</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">21506741</pub-id>
</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Minikel</surname><given-names>EV</given-names></name>, <name><surname>Painter</surname><given-names>JL</given-names></name>, <name><surname>Dong</surname><given-names>CC</given-names></name>, <name><surname>Nelson</surname><given-names>MR</given-names></name>. <article-title>Refining the impact of genetic evidence on clinical success</article-title>. <source>Nature</source>. <year>2024</year>:<fpage>1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Fingerlin</surname><given-names>TE</given-names></name>, <name><surname>Murphy</surname><given-names>E</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Peljto</surname><given-names>AL</given-names></name>, <name><surname>Brown</surname><given-names>KK</given-names></name>, <name><surname>Steele</surname><given-names>MP</given-names></name>, <etal/>
<article-title>Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>(<issue>6</issue>):<fpage>613</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="pmid">23583980</pub-id>
</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Reynolds</surname><given-names>CJ</given-names></name>, <name><surname>Sisodia</surname><given-names>R</given-names></name>, <name><surname>Barber</surname><given-names>C</given-names></name>, <name><surname>Moffatt</surname><given-names>M</given-names></name>, <name><surname>Minelli</surname><given-names>C</given-names></name>, <name><surname>De Matteis</surname><given-names>S</given-names></name>, <etal/>
<article-title>What role for asbestos in idiopathic pulmonary fibrosis? Findings from the IPF job exposures case&#x02013;control study</article-title>. <source>Occup Environ Med</source>. <year>2023</year>;<volume>80</volume>(<issue>2</issue>):<fpage>97</fpage>&#x02013;<lpage>103</lpage>.<pub-id pub-id-type="pmid">36635100</pub-id>
</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Donoghue</surname><given-names>LJ</given-names></name>, <name><surname>Stockwell</surname><given-names>AD</given-names></name>, <name><surname>Neighbors</surname><given-names>M</given-names></name>, <name><surname>Sheng</surname><given-names>RX</given-names></name>, <name><surname>Prabhakaran</surname><given-names>R</given-names></name>, <name><surname>Wolters</surname><given-names>PJ</given-names></name>, <etal/>
<article-title>Identification of a Genetic Susceptibility Locus for Idiopathic Pulmonary Fibrosis in the 16p Subtelomere Using Whole-Genome Sequencing</article-title>. <source>American Journal of Respiratory and Critical Care Medicine</source>. <year>2023</year>;<volume>207</volume>(<issue>7</issue>):<fpage>941</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">36603154</pub-id>
</mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Martinez</surname><given-names>FJ</given-names></name>, <name><surname>Yow</surname><given-names>E</given-names></name>, <name><surname>Flaherty</surname><given-names>KR</given-names></name>, <name><surname>Snyder</surname><given-names>LD</given-names></name>, <name><surname>Durheim</surname><given-names>MT</given-names></name>, <name><surname>Wisniewski</surname><given-names>SR</given-names></name>, <etal/>
<article-title>Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>18</issue>):<fpage>1841</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">33974018</pub-id>
</mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Raghu</surname><given-names>G</given-names></name>, <name><surname>Remy-Jardin</surname><given-names>M</given-names></name>, <name><surname>Myers</surname><given-names>JL</given-names></name>, <name><surname>Richeldi</surname><given-names>L</given-names></name>, <name><surname>Ryerson</surname><given-names>CJ</given-names></name>, <name><surname>Lederer</surname><given-names>DJ</given-names></name>, <etal/>
<article-title>Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2018</year>;<volume>198</volume>(<issue>5</issue>):<fpage>e44</fpage>&#x02013;<lpage>68</lpage>.<pub-id pub-id-type="pmid">30168753</pub-id>
</mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>Society</surname><given-names>ER</given-names></name>, <article-title>American Thoracic Society. American Thoracic Society</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2002</year>;<volume>165</volume>(<issue>2</issue>):<fpage>277</fpage>&#x02013;<lpage>304</lpage>.<pub-id pub-id-type="pmid">11790668</pub-id>
</mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Raghu</surname><given-names>G</given-names></name>, <name><surname>Collard</surname><given-names>HR</given-names></name>, <name><surname>Egan</surname><given-names>JJ</given-names></name>, <name><surname>Martinez</surname><given-names>FJ</given-names></name>, <name><surname>Behr</surname><given-names>J</given-names></name>, <name><surname>Brown</surname><given-names>KK</given-names></name>, <etal/>
<article-title>An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2011</year>;<volume>183</volume>(<issue>6</issue>):<fpage>788</fpage>&#x02013;<lpage>824</lpage>.<pub-id pub-id-type="pmid">21471066</pub-id>
</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Das</surname><given-names>S</given-names></name>, <name><surname>Forer</surname><given-names>L</given-names></name>, <name><surname>Sch&#x000f6;nherr</surname><given-names>S</given-names></name>, <name><surname>Sidore</surname><given-names>C</given-names></name>, <name><surname>Locke</surname><given-names>AE</given-names></name>, <name><surname>Kwong</surname><given-names>A</given-names></name>, <etal/>
<article-title>Next-generation genotype imputation service and methods</article-title>. <source>Nat Genet</source>. <year>2016</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1284</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">27571263</pub-id>
</mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>CC</given-names></name>, <name><surname>Chow</surname><given-names>CC</given-names></name>, <name><surname>Tellier</surname><given-names>LC</given-names></name>, <name><surname>Vattikuti</surname><given-names>S</given-names></name>, <name><surname>Purcell</surname><given-names>SM</given-names></name>, <name><surname>Lee</surname><given-names>JJ</given-names></name>. <article-title>Second-generation PLINK: rising to the challenge of larger and richer datasets</article-title>. <source>Gigascience</source>. <year>2015</year>;<volume>4</volume>(<issue>1</issue>):<fpage>s13742</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Willer</surname><given-names>CJ</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Abecasis</surname><given-names>GR</given-names></name>. <article-title>METAL: fast and efficient meta-analysis of genomewide association scans</article-title>. <source>Bioinformatics</source>. <year>2010</year>;<volume>26</volume>(<issue>17</issue>):<fpage>2190</fpage>&#x02013;<lpage>1</lpage>.<pub-id pub-id-type="pmid">20616382</pub-id>
</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Bulik-Sullivan</surname><given-names>BK</given-names></name>, <name><surname>Loh</surname><given-names>P</given-names></name>, <name><surname>Finucane</surname><given-names>HK</given-names></name>, <name><surname>Ripke</surname><given-names>S</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <collab>Schizophrenia Working Group of the Psychiatric Genomics Consortium</collab>, <etal/>
<article-title>LD Score regression distinguishes confounding from polygenicity in genome-wide association studies</article-title>. <source>Nat Genet</source>. <year>2015</year>;<volume>47</volume>(<issue>3</issue>):<fpage>291</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">25642630</pub-id>
</mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Ferreira</surname><given-names>T</given-names></name>, <name><surname>Morris</surname><given-names>AP</given-names></name>, <name><surname>Medland</surname><given-names>SE</given-names></name>, <collab>Genetic Investigation of ANthropometric Traits (GIANT) Consortium, DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium</collab>, <etal/>
<article-title>Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits</article-title>. <source>Nat Genet</source>. <year>2012</year>;<volume>44</volume>(<issue>4</issue>):<fpage>369</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">22426310</pub-id>
</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Kurilshikov</surname><given-names>A</given-names></name>, <name><surname>Medina-Gomez</surname><given-names>C</given-names></name>, <name><surname>Bacigalupe</surname><given-names>R</given-names></name>, <name><surname>Radjabzadeh</surname><given-names>D</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Demirkan</surname><given-names>A</given-names></name>, <etal/>
<article-title>Large-scale association analyses identify host factors influencing human gut microbiome composition</article-title>. <source>Nat Genet</source>. <year>2021</year>;<volume>53</volume>(<issue>2</issue>):<fpage>156</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">33462485</pub-id>
</mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name>, <name><surname>Li</surname><given-names>M</given-names></name>, <name><surname>Hakonarson</surname><given-names>H</given-names></name>. <article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title>. <source>Nucleic Acids Res</source>. <year>2010</year>;<volume>38</volume>(<issue>16</issue>):<fpage>e164</fpage>.<pub-id pub-id-type="pmid">20601685</pub-id>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Wakefield</surname><given-names>J.</given-names></name>
<article-title>Bayes factors for genome-wide association studies: comparison with P-values</article-title>. <source>Genetic Epidemiology: The Official Publication of the International Genetic Epidemiology Society</source>. <year>2009</year>;<volume>33</volume>(<issue>1</issue>):<fpage>79</fpage>&#x02013;<lpage>86</lpage>.</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Lonsdale</surname><given-names>J</given-names></name>, <name><surname>Thomas</surname><given-names>J</given-names></name>, <name><surname>Salvatore</surname><given-names>M</given-names></name>, <name><surname>Phillips</surname><given-names>R</given-names></name>, <name><surname>Lo</surname><given-names>E</given-names></name>, <name><surname>Shad</surname><given-names>S</given-names></name>, <etal/>
<article-title>The genotype-tissue expression (GTEx) project</article-title>. <source>Nat Genet</source>. <year>2013</year>;<volume>45</volume>(<issue>6</issue>):<fpage>580</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">23715323</pub-id>
</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Giambartolomei</surname><given-names>C</given-names></name>, <name><surname>Vukcevic</surname><given-names>D</given-names></name>, <name><surname>Schadt</surname><given-names>EE</given-names></name>, <name><surname>Franke</surname><given-names>L</given-names></name>, <name><surname>Hingorani</surname><given-names>AD</given-names></name>, <name><surname>Wallace</surname><given-names>C</given-names></name>, <etal/>
<article-title>Bayesian test for colocalisation between pairs of genetic association studies using summary statistics</article-title>. <source>PLoS genetics</source>. <year>2014</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e1004383</fpage>.<pub-id pub-id-type="pmid">24830394</pub-id>
</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Biddie</surname><given-names>SC</given-names></name>, <name><surname>Weykopf</surname><given-names>G</given-names></name>, <name><surname>Hird</surname><given-names>EF</given-names></name>, <name><surname>Friman</surname><given-names>ET</given-names></name>, <name><surname>Bickmore</surname><given-names>WA</given-names></name>. <article-title>DNA-binding factor footprints and enhancer RNAs identify functional non-coding genetic variants</article-title>. <source>Genome Biol</source>. <year>2024</year>;<volume>25</volume>(<issue>1</issue>):<fpage>208</fpage>.<pub-id pub-id-type="pmid">39107801</pub-id>
</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Leavy</surname><given-names>OC</given-names></name>, <name><surname>Allen</surname><given-names>RJ</given-names></name>, <name><surname>Kraven</surname><given-names>LM</given-names></name>, <name><surname>Morgan</surname><given-names>AD</given-names></name>, <name><surname>Tobin</surname><given-names>MD</given-names></name>, <name><surname>Quint</surname><given-names>JK</given-names></name>, <etal/>
<article-title>No title</article-title>. <source>P32 Using genetic information to define idiopathic pulmonary fibrosis in UK biobank</source>. <year>2022</year>.</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Ballester</surname><given-names>B</given-names></name>, <name><surname>Milara</surname><given-names>J</given-names></name>, <name><surname>Cortijo</surname><given-names>J</given-names></name>. <article-title>The role of mucin 1 in respiratory diseases</article-title>. <source>European Respiratory Review</source>. <year>2021</year>;<volume>30</volume>(<issue>159</issue>).</mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Milara</surname><given-names>J</given-names></name>, <name><surname>Ballester</surname><given-names>B</given-names></name>, <name><surname>Montero</surname><given-names>P</given-names></name>, <name><surname>Escriva</surname><given-names>J</given-names></name>, <name><surname>Artigues</surname><given-names>E</given-names></name>, <name><surname>Al&#x000f3;s</surname><given-names>M</given-names></name>, <etal/>
<article-title>MUC1 intracellular bioactivation mediates lung fibrosis</article-title>. <source>Thorax</source>. <year>2020</year>;<volume>75</volume>(<issue>2</issue>):<fpage>132</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">31801904</pub-id>
</mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Ballester</surname><given-names>B</given-names></name>, <name><surname>Milara</surname><given-names>J</given-names></name>, <name><surname>Cortijo</surname><given-names>J</given-names></name>. <article-title>Mucins as a new frontier in pulmonary fibrosis</article-title>. <source>Journal of Clinical Medicine</source>. <year>2019</year>;<volume>8</volume>(<issue>9</issue>):<fpage>1447</fpage>.<pub-id pub-id-type="pmid">31514468</pub-id>
</mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Ma</surname><given-names>Y</given-names></name>, <name><surname>Han</surname><given-names>X</given-names></name>, <name><surname>Zan</surname><given-names>S</given-names></name>, <name><surname>Liu</surname><given-names>H</given-names></name>, <name><surname>Zhou</surname><given-names>X</given-names></name>, <name><surname>Zhao</surname><given-names>D</given-names></name>, <etal/>
<article-title>Microrna363&#x02013;5p targets thrombospondin3 to regulate pathological cardiac remodeling</article-title>. <source>Mol Cell Biochem</source>. <year>2024</year>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>.</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Bergmeier</surname><given-names>V</given-names></name>, <name><surname>Etich</surname><given-names>J</given-names></name>, <name><surname>Pitzler</surname><given-names>L</given-names></name>, <name><surname>Frie</surname><given-names>C</given-names></name>, <name><surname>Koch</surname><given-names>M</given-names></name>, <name><surname>Fischer</surname><given-names>M</given-names></name>, <etal/>
<article-title>Identification of a myofibroblast-specific expression signature in skin wounds</article-title>. <source>Matrix Biology</source>. <year>2018</year>;<volume>65</volume>:<fpage>59</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">28797711</pub-id>
</mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Y</given-names></name>, <name><surname>Stein</surname><given-names>E</given-names></name>, <name><surname>Oliver</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Brunken</surname><given-names>WJ</given-names></name>, <name><surname>Koch</surname><given-names>M</given-names></name>, <etal/>
<article-title>Novel role for Netrins in regulating epithelial behavior during lung branching morphogenesis</article-title>. <source>Current biology</source>. <year>2004</year>;<volume>14</volume>(<issue>10</issue>):<fpage>897</fpage>&#x02013;<lpage>905</lpage>.<pub-id pub-id-type="pmid">15186747</pub-id>
</mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Neumark</surname><given-names>N</given-names></name>, <name><surname>Cosme</surname><given-names>C</given-names><suffix>Jr</suffix></name>, <name><surname>Rose</surname><given-names>K</given-names></name>, <name><surname>Kaminski</surname><given-names>N</given-names></name>. <article-title>The idiopathic pulmonary fibrosis cell atlas</article-title>. <source>American Journal of Physiology-Lung Cellular and Molecular Physiology</source>. <year>2020</year>;<volume>319</volume>(<issue>6</issue>):<fpage>L887</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">32996785</pub-id>
</mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Adams</surname><given-names>TS</given-names></name>, <name><surname>Schupp</surname><given-names>JC</given-names></name>, <name><surname>Poli</surname><given-names>S</given-names></name>, <name><surname>Ayaub</surname><given-names>EA</given-names></name>, <name><surname>Neumark</surname><given-names>N</given-names></name>, <name><surname>Ahangari</surname><given-names>F</given-names></name>, <etal/>
<article-title>Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis</article-title>. <source>Science advances</source>. <year>2020</year>;<volume>6</volume>(<issue>28</issue>):<fpage>eaba1983</fpage>.<pub-id pub-id-type="pmid">32832599</pub-id>
</mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Reyfman</surname><given-names>PA</given-names></name>, <name><surname>Walter</surname><given-names>JM</given-names></name>, <name><surname>Joshi</surname><given-names>N</given-names></name>, <name><surname>Anekalla</surname><given-names>KR</given-names></name>, <name><surname>McQuattie-Pimentel</surname><given-names>AC</given-names></name>, <name><surname>Chiu</surname><given-names>S</given-names></name>, <etal/>
<article-title>Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2019</year>;<volume>199</volume>(<issue>12</issue>):<fpage>1517</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="pmid">30554520</pub-id>
</mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Morse</surname><given-names>C</given-names></name>, <name><surname>Tabib</surname><given-names>T</given-names></name>, <name><surname>Sembrat</surname><given-names>J</given-names></name>, <name><surname>Buschur</surname><given-names>KL</given-names></name>, <name><surname>Bittar</surname><given-names>HT</given-names></name>, <name><surname>Valenzi</surname><given-names>E</given-names></name>, <etal/>
<article-title>Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis</article-title>. <source>European Respiratory Journal</source>. <year>2019</year>;<fpage>54</fpage>(2).</mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Sakornsakolpat</surname><given-names>P</given-names></name>, <name><surname>McCormack</surname><given-names>M</given-names></name>, <name><surname>Bakke</surname><given-names>P</given-names></name>, <name><surname>Gulsvik</surname><given-names>A</given-names></name>, <name><surname>Make</surname><given-names>BJ</given-names></name>, <name><surname>Crapo</surname><given-names>JD</given-names></name>, <etal/>
<article-title>Genome-wide association analysis of single-breath DLCO</article-title>. <source>American journal of respiratory cell and molecular biology</source>. <year>2019</year>;<volume>60</volume>(<issue>5</issue>):<fpage>523</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">30694715</pub-id>
</mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Lejmi</surname><given-names>E</given-names></name>, <name><surname>Leconte</surname><given-names>L</given-names></name>, <name><surname>P&#x000e9;dron-Mazoyer</surname><given-names>S</given-names></name>, <name><surname>Ropert</surname><given-names>S</given-names></name>, <name><surname>Raoul</surname><given-names>W</given-names></name>, <name><surname>Lavalette</surname><given-names>S</given-names></name>, <etal/>
<article-title>Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B</article-title>. <source>Proceedings of the National Academy of Sciences</source>. <year>2008</year>;<volume>105</volume>(<issue>34</issue>):<fpage>12491</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>BD</given-names></name>, <name><surname>Ii</surname><given-names>M</given-names></name>, <name><surname>Park</surname><given-names>KW</given-names></name>, <name><surname>Suli</surname><given-names>A</given-names></name>, <name><surname>Sorensen</surname><given-names>LK</given-names></name>, <name><surname>Larrieu-Lahargue</surname><given-names>F</given-names></name>, <etal/>
<article-title>Netrins promote developmental and therapeutic angiogenesis</article-title>. <source>Science</source>. <year>2006</year>;<volume>313</volume>(<issue>5787</issue>):<fpage>640</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">16809490</pub-id>
</mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Nacht</surname><given-names>M</given-names></name>, <name><surname>Martin</surname><given-names>TBS</given-names></name>, <name><surname>Byrne</surname><given-names>A</given-names></name>, <name><surname>Klinger</surname><given-names>KW</given-names></name>, <name><surname>Teicher</surname><given-names>BA</given-names></name>, <name><surname>Madden</surname><given-names>SL</given-names></name>, <etal/>
<article-title>Netrin-4 regulates angiogenic responses and tumor cell growth</article-title>. <source>Exp Cell Res</source>. <year>2009</year>;<volume>315</volume>(<issue>5</issue>):<fpage>784</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">19094984</pub-id>
</mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>May</surname><given-names>J</given-names></name>, <name><surname>Mitchell</surname><given-names>JA</given-names></name>, <name><surname>Jenkins</surname><given-names>RG</given-names></name>. <article-title>Beyond epithelial damage: vascular and endothelial contributions to idiopathic pulmonary fibrosis</article-title>. <source>J Clin Invest</source>. <year>2023</year>;<volume>133</volume>(<issue>18</issue>):<fpage>e172058</fpage>.<pub-id pub-id-type="pmid">37712420</pub-id>
</mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Manichaikul</surname><given-names>A</given-names></name>, <name><surname>Hoffman</surname><given-names>EA</given-names></name>, <name><surname>Smolonska</surname><given-names>J</given-names></name>, <name><surname>Gao</surname><given-names>W</given-names></name>, <name><surname>Cho</surname><given-names>MH</given-names></name>, <name><surname>Baumhauer</surname><given-names>H</given-names></name>, <etal/>
<article-title>Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study</article-title>. <source>American journal of respiratory and critical care medicine</source>. <year>2014</year>;<volume>189</volume>(<issue>4</issue>):<fpage>408</fpage>&#x02013;<lpage>18</lpage>.<pub-id pub-id-type="pmid">24383474</pub-id>
</mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Peat</surname><given-names>G</given-names></name>, <name><surname>Jones</surname><given-names>W</given-names></name>, <name><surname>Nuhn</surname><given-names>M</given-names></name>, <name><surname>Marug&#x000e1;n</surname><given-names>JC</given-names></name>, <name><surname>Newell</surname><given-names>W</given-names></name>, <name><surname>Dunham</surname><given-names>I</given-names></name>, <etal/>
<article-title>The open targets post-GWAS analysis pipeline</article-title>. <source>Bioinformatics</source>. <year>2020</year>;<volume>36</volume>(<issue>9</issue>):<fpage>2936</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">31930349</pub-id>
</mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>Wain</surname><given-names>LV</given-names></name>, <name><surname>Sayers</surname><given-names>I</given-names></name>, <name><surname>Soler Artigas</surname><given-names>M</given-names></name>, <name><surname>Portelli</surname><given-names>MA</given-names></name>, <name><surname>Zeggini</surname><given-names>E</given-names></name>, <name><surname>Obeidat</surname><given-names>M</given-names></name>, <etal/>
<article-title>Whole exome re-sequencing implicates CCDC38 and cilia structure and function in resistance to smoking related airflow obstruction</article-title>. <source>PLoS genetics</source>. <year>2014</year>;<volume>10</volume>(<issue>5</issue>):<fpage>e1004314</fpage>.<pub-id pub-id-type="pmid">24786987</pub-id>
</mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name><surname>Ansar</surname><given-names>M</given-names></name>, <name><surname>Ranza</surname><given-names>E</given-names></name>, <name><surname>Shetty</surname><given-names>M</given-names></name>, <name><surname>Paracha</surname><given-names>SA</given-names></name>, <name><surname>Azam</surname><given-names>M</given-names></name>, <name><surname>Kern</surname><given-names>I</given-names></name>, <etal/>
<article-title>Taurine treatment of retinal degeneration and cardiomyopathy in a consanguineous family with SLC6A6 taurine transporter deficiency</article-title>. <source>Hum Mol Genet</source>. <year>2020</year>;<volume>29</volume>(<issue>4</issue>):<fpage>618</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">31903486</pub-id>
</mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>X</given-names></name>, <name><surname>Patters</surname><given-names>AB</given-names></name>, <name><surname>Ito</surname><given-names>T</given-names></name>, <name><surname>Azuma</surname><given-names>J</given-names></name>, <name><surname>Schaffer</surname><given-names>SW</given-names></name>, <name><surname>Chesney</surname><given-names>RW</given-names></name>. <article-title>Knockout of the TauT gene predisposes C57BL/6 mice to streptozotocin-induced diabetic nephropathy</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>1</issue>):<fpage>e0117718</fpage>.<pub-id pub-id-type="pmid">25629817</pub-id>
</mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name><surname>Baliou</surname><given-names>S</given-names></name>, <name><surname>Adamaki</surname><given-names>M</given-names></name>, <name><surname>Ioannou</surname><given-names>P</given-names></name>, <name><surname>Pappa</surname><given-names>A</given-names></name>, <name><surname>Panayiotidis</surname><given-names>MI</given-names></name>, <name><surname>Spandidos</surname><given-names>DA</given-names></name>, <etal/>
<article-title>Protective role of taurine against oxidative stress</article-title>. <source>Molecular medicine reports</source>. <year>2021</year>;<volume>24</volume>(<issue>2</issue>):<fpage>605</fpage>.<pub-id pub-id-type="pmid">34184084</pub-id>
</mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name><surname>Gurujeyalakshmi</surname><given-names>G</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Giri</surname><given-names>SN</given-names></name>. <article-title>Taurine and niacin block lung injury and fibrosis by downregulating bleomycin-induced activation of transcription nuclear factor-&#x003ba;B in mice</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2000</year>;<volume>293</volume>(<issue>1</issue>):<fpage>82</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">10734156</pub-id>
</mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><name><surname>Lichou</surname><given-names>F</given-names></name>, <name><surname>Trynka</surname><given-names>G</given-names></name>. <article-title>Functional studies of GWAS variants are gaining momentum</article-title>. <source>Nature communications</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>6283</fpage>.</mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name><surname>Thurman</surname><given-names>RE</given-names></name>, <name><surname>Rynes</surname><given-names>E</given-names></name>, <name><surname>Humbert</surname><given-names>R</given-names></name>, <name><surname>Vierstra</surname><given-names>J</given-names></name>, <name><surname>Maurano</surname><given-names>MT</given-names></name>, <name><surname>Haugen</surname><given-names>E</given-names></name>, <etal/>
<article-title>The accessible chromatin landscape of the human genome</article-title>. <source>Nature</source>. <year>2012</year>;<volume>489</volume>(<issue>7414</issue>):<fpage>75</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">22955617</pub-id>
</mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name><surname>Javierre</surname><given-names>BM</given-names></name>, <name><surname>Burren</surname><given-names>OS</given-names></name>, <name><surname>Wilder</surname><given-names>SP</given-names></name>, <name><surname>Kreuzhuber</surname><given-names>R</given-names></name>, <name><surname>Hill</surname><given-names>SM</given-names></name>, <name><surname>Sewitz</surname><given-names>S</given-names></name>, <etal/>
<article-title>Lineage-specific genome architecture links enhancers and non-coding disease variants to target gene promoters</article-title>. <source>Cell</source>. <year>2016</year>;<volume>167</volume>(<issue>5</issue>):<fpage>1369</fpage>,<lpage>1384. e19</lpage>.<pub-id pub-id-type="pmid">27863249</pub-id>
</mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1.</label><caption><title>Study overview.</title><p id="P38">SNPs: Single Nucleotide Polymorphisms. WGS: Whole-genome sequencing data.</p></caption><graphic xlink:href="nihpp-2025.01.30.25321017v1-f0001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2.</label><caption><title>Manhattan plot of meta-analysis results.</title><p id="P39">The y-axis shows the transformed p-values (&#x02212;log10[p-value]) while the x-axis represents chromosome positions. The horizontal red line corresponds to the genome-wide threshold (<italic toggle="yes">p</italic>=5.0&#x000d7;10<sup>&#x02212;8</sup>) and the blue line shows the suggestive significance threshold (<italic toggle="yes">p</italic>=5.0&#x000d7;10<sup>&#x02212;5</sup>). The genomic inflation factor of the meta-analysis results did not show major deviations from the null hypothesis of no association. Newly discovered annotated genes are highlighted in red and bold. The plot has been truncated at <italic toggle="yes">p</italic>=1&#x000d7;10<sup>&#x02212;35</sup>. The most significant previously reported <italic toggle="yes">MUC5B</italic> signal (rs357058950) has a p&#x0003c;5.00&#x000d7;10<sup>&#x02212;121</sup>.</p></caption><graphic xlink:href="nihpp-2025.01.30.25321017v1-f0002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3.</label><caption><title>Region plots and forest plots of the three signals of interest:</title><p id="P40">a) 1q22 region; b) 3p25.1 region; and c) 12q23.1 region. In region plots, the y-axis shows the transformed p-values (&#x02212;log10[p-value]), while the x-axis represents chromosomal positions (GRCh38). The genome-wide significance threshold (<italic toggle="yes">p</italic> =5.0&#x000d7;10<sup>&#x02212;8</sup>) is indicated by the horizontal dashed line. Linkage disequilibrium values (r2) are presented according to the LD colour scheme of the upper left legend. Plots were generated using LocusZoom (<ext-link xlink:href="http://locuszoom.org/" ext-link-type="uri">http://locuszoom.org/</ext-link>).</p></caption><graphic xlink:href="nihpp-2025.01.30.25321017v1-f0003" position="float"/></fig><table-wrap position="float" id="T1" orientation="landscape"><label>Table 1.</label><caption><p id="P41">New genome-wide significant association signals</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1"/><th colspan="4" align="center" valign="middle" rowspan="1">This study</th><th colspan="3" align="center" valign="middle" rowspan="1">Replication</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Region (CHR:BP)</th><th align="center" valign="middle" rowspan="1" colspan="1">SNP</th><th align="center" valign="middle" rowspan="1" colspan="1">Location (nearest gene)</th><th align="center" valign="middle" rowspan="1" colspan="1">A1/A2</th><th align="center" valign="middle" rowspan="1" colspan="1">A1 Freq.</th><th align="center" valign="middle" rowspan="1" colspan="1">OR (95%)</th><th align="center" valign="middle" rowspan="1" colspan="1">P</th><th align="center" valign="middle" rowspan="1" colspan="1">N<sup>o</sup> SNPs in credible set (largest PIP)</th><th align="center" valign="middle" rowspan="1" colspan="1">A1 Freq.</th><th align="center" valign="middle" rowspan="1" colspan="1">OR (95%)</th><th align="center" valign="middle" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1q22 (1:155179278)</td><td align="center" valign="middle" rowspan="1" colspan="1">rs9426886</td><td align="center" valign="middle" rowspan="1" colspan="1">Intronic (<italic toggle="yes">TRIM46)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">T/A</td><td align="center" valign="middle" rowspan="1" colspan="1">0.568</td><td align="center" valign="middle" rowspan="1" colspan="1">1.162 (1.106&#x02013;1.219)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.53x10<sup>&#x02212;9</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">7 (0.208)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.555</td><td align="center" valign="middle" rowspan="1" colspan="1">1.051 (1.013&#x02013;1.091)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.02x10<sup>&#x02212;3</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3p25.1 (3:14270502)</td><td align="center" valign="middle" rowspan="1" colspan="1">rs112271207</td><td align="center" valign="middle" rowspan="1" colspan="1">Intergenic (<italic toggle="yes">LSM3\LINC01267)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">T/C</td><td align="center" valign="middle" rowspan="1" colspan="1">0.060</td><td align="center" valign="middle" rowspan="1" colspan="1">1.385 (1.259&#x02013;1.524)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.23x10<sup>&#x02212;11</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">9 (0.691)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.069</td><td align="center" valign="middle" rowspan="1" colspan="1">1.111 (1.031&#x02013;1.197)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.64x10<sup>&#x02212;3</sup></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12q23.1 (12:95866696)</td><td align="center" valign="middle" rowspan="1" colspan="1">rs7957346</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x02019; UTR (<italic toggle="yes">SNRPF)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">A/C</td><td align="center" valign="middle" rowspan="1" colspan="1">0.582</td><td align="center" valign="middle" rowspan="1" colspan="1">1.153 (1.098&#x02013;1.212)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.56x10<sup>&#x02212;8</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">5 (0.376)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.588</td><td align="center" valign="middle" rowspan="1" colspan="1">1.080 (1.041&#x02013;1.120)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.69x10<sup>&#x02212;5</sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P42">A1: effect allele; A2: non-effect allele; Freq: Frequency; OR: Odds Ratio; PIP: posterior inclusion probability; Coordinates in GRCh38.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="landscape"><label>Table 2.</label><caption><p id="P43">Summary of variant to gene mapping and functional information</p></caption><table frame="box" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Signal<xref rid="TFN7" ref-type="table-fn">*</xref></th><th align="center" valign="middle" rowspan="1" colspan="1">Location (nearest gene)</th><th align="center" valign="middle" rowspan="1" colspan="1">Gene implicated by eQTL (GTEx: tissue, highest posterior probability of shared causal variant)</th><th align="center" valign="middle" rowspan="1" colspan="1">Other gene evidence<sup><xref rid="TFN2" ref-type="table-fn">#</xref></sup></th><th align="center" valign="middle" rowspan="1" colspan="1">PheWAS (aligned to IPF risk allele)<sup><xref rid="TFN2" ref-type="table-fn">#</xref></sup></th><th align="center" valign="middle" rowspan="1" colspan="1">Open Chromatin<xref rid="TFN6" ref-type="table-fn">**</xref></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1q22 (rs9426886)</td><td align="center" valign="middle" rowspan="1" colspan="1">Intronic (<italic toggle="yes">TRIM46)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">MUC1</italic> (whole blood, 0.616)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">THBS3</italic>, <italic toggle="yes">ADAM15</italic> (sQTL<sup><xref rid="TFN3" ref-type="table-fn">1</xref></sup>; DHS-promoter correlation<sup><xref rid="TFN4" ref-type="table-fn">2</xref></sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">increased haematocrit, decreased urate</td><td align="center" valign="middle" rowspan="1" colspan="1">DHS; H3K27ac</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3p25.1 (rs112271207)</td><td align="center" valign="middle" rowspan="1" colspan="1">Intergenic (<italic toggle="yes">LSM3\LINC01267)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">SLC6A6</italic> (PCHiC<sup><xref rid="TFN5" ref-type="table-fn">3</xref></sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">decreased lung function</td><td align="center" valign="middle" rowspan="1" colspan="1">ATACseq; H3K27ac</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12q23.1 (rs7957346)</td><td align="center" valign="middle" rowspan="1" colspan="1">3&#x02019; UTR (<italic toggle="yes">SNRPF)</italic></td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">NTN4</italic> (lung, 0.649)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">NTN4</italic> (sQTL<sup><xref rid="TFN4" ref-type="table-fn">2</xref></sup>)</td><td align="center" valign="middle" rowspan="1" colspan="1">decreased lung function</td><td align="center" valign="middle" rowspan="1" colspan="1">ATACseq; H3K27ac</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>#</label><p id="P44">Open Targets Genetics:</p></fn><fn id="TFN3"><label>1.</label><p id="P45">Splice QTL (source: GTEx);</p></fn><fn id="TFN4"><label>2.</label><p id="P46">DHS-promoter capture (source: Thurman et al 2012 (<xref rid="R56" ref-type="bibr">56</xref>));</p></fn><fn id="TFN5"><label>3.</label><p id="P47">Promotor Capture HiC in blood-derived endothelial precursors, macrophages, megakaryocytes, naive B cells and neutrophils (from Open Targets Genetics, source: Javierre et al 2016 (<xref rid="R57" ref-type="bibr">57</xref>).</p></fn><fn id="TFN6"><label>**</label><p id="P48">Biddie et al 2023 (<xref rid="R31" ref-type="bibr">31</xref>).</p></fn><fn id="TFN7"><label>*</label><p id="P49">Minimum study-level imputation quality Rsq for each variant: rs9426886:0.936, rs112271207:0.929, rs7957346:0.991.</p></fn><fn id="TFN8"><p id="P50">See <xref rid="SD1" ref-type="supplementary-material">Table S3</xref> for full results.</p></fn></table-wrap-foot></table-wrap></floats-group></article>